These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29188425)

  • 1. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.
    Yee MK; Nafee T; Daaboul Y; Korjian S; AlKhalfan F; Kerneis M; Wiest C; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM
    J Thromb Thrombolysis; 2018 Jan; 45(1):1-8. PubMed ID: 29188425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
    Gibson CM; Korjian S; Chi G; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Lopes RD; Gold A; Cohen AT; Harrington RA;
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28698258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
    Gibson CM; Chi G; Halaby R; Korjian S; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Gold A; Bandman O; Harrington RA; Cohen AT;
    Circulation; 2017 Feb; 135(7):648-655. PubMed ID: 27881569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
    Chi G; Gibson CM; Kalayci A; Cohen AT; Hernandez AF; Hull RD; Kahe F; Jafarizade M; Sharfaei S; Liu Y; Harrington RA; Goldhaber SZ
    Intensive Care Med; 2019 Apr; 45(4):477-487. PubMed ID: 30778649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
    Gibson CM; Halaby R; Korjian S; Daaboul Y; Arbetter DF; Yee MK; Goldhaber SZ; Hull R; Hernandez AF; Lu SP; Bandman O; Leeds JM; Gold A; Harrington RA; Cohen AT;
    Am Heart J; 2017 Mar; 185():93-100. PubMed ID: 28267480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.
    Gibson CM; Nafee T; Yee MK; Chi G; Korjian S; Daaboul Y; AlKhalfan F; Kerneis M; Goldhaber SZ; Hull R; Hernandez AF; Cohen AT; Harrington RA
    Am Heart J; 2018 Apr; 198():84-90. PubMed ID: 29653652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.
    Cohen AT; Harrington R; Goldhaber SZ; Hull R; Gibson CM; Hernandez AF; Kitt MM; Lorenz TJ
    Am Heart J; 2014 Mar; 167(3):335-41. PubMed ID: 24576517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
    Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
    Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
    Miller KM; Brenner MJ
    Drugs; 2019 Feb; 79(3):291-302. PubMed ID: 30719631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
    Ageno W; Lopes RD; Yee MK; Hernandez A; Hull RD; Goldhaber SZ; Gibson CM; Cohen AT
    J Thromb Haemost; 2019 Dec; 17(12):2089-2098. PubMed ID: 31392827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.
    Arbetter DF; Jain P; Yee MK; Michalak N; Hernandez AF; Hull RD; Goldhaber SZ; Harrington RA; Gold A; Cohen AT; Gibson CM
    Pharm Stat; 2017 Nov; 16(6):445-450. PubMed ID: 28840662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.
    Guy H; Laskier V; Fisher M; Neuman WR; Bucior I; Deitelzweig S; Cohen AT
    Pharmacoeconomics; 2019 May; 37(5):701-714. PubMed ID: 30578462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
    Garland SG; DeRemer CE; Smith SM; Gums JG
    Ann Pharmacother; 2018 Jun; 52(6):554-561. PubMed ID: 29338293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial.
    Ageno W; Lopes RD; Yee MK; Hernandez A; Hull R; Goldhaber SZ; Gibson CM; Cohen AT
    J Thromb Thrombolysis; 2020 Feb; 49(2):214-219. PubMed ID: 31493287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
    Cohen AT; Harrington RA; Goldhaber SZ; Hull RD; Wiens BL; Gold A; Hernandez AF; Gibson CM;
    N Engl J Med; 2016 Aug; 375(6):534-44. PubMed ID: 27232649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of betrixaban and its role in clinical practice.
    Lekura J; Kalus JS
    Am J Health Syst Pharm; 2018 Aug; 75(15):1095-1102. PubMed ID: 29941506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.
    Kalayci A; Gibson CM; Chi G; Yee MK; Korjian S; Datta S; Nafee T; Gurin M; Haroian N; Qamar I; Hull RD; Hernandez AF; Cohen AT; Harrington RA; Goldhaber SZ
    Thromb Haemost; 2018 Dec; 118(12):2046-2052. PubMed ID: 30419597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom.
    Guy H; Laskier V; Fisher M; Bucior I; Deitelzweig S; Cohen AT
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):259-267. PubMed ID: 31215264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial.
    Chi G; Gibson CM; Liu Y; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Goldhaber SZ
    Am J Hematol; 2019 Jan; 94(1):21-28. PubMed ID: 30252149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
    Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
    Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.